Table 2.
Acceptability ratings for aspects of the BPaL (Nix) regimen and the individualized treatment regimena
| Overall (N = 182) | Indonesia | Kyrgyzstan | Nigeria | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ITR | BPaL | ITR | BPaL | ITR | BPaL | ITR | BPaL | ||
| Baseline assessment and monitoring of treatment efficacy | Total | 144 | 144 | 46 | 45 | 51 | 50 | 47 | 49 |
| Acceptable | 106 (74%) | 127 (88%) | 35 (76%) | 38 (84%) | 43 (84%) | 47 (94%) | 28 (60%) | 42 (86%) | |
| Neutral | 26 (18%) | 14 (10%) | 7 (15%) | 7 (16%) | 6 (12%) | 2 (4%) | 13 (28%) | 5 (10%) | |
| Unacceptable | 12 (8%) | 3 (2%) | 4 (9%) | 0 (0%) | 2 (4%) | 1 (2%) | 6 (13%) | 2 (4%) | |
| Treatment safety monitoring | Total | 141 | 140 | 44 | 43 | 52 | 52 | 45 | 45 |
| Acceptable | 108 (77%) | 115 (84%) | 39 (89%) | 31 (72%) | 42 (81%) | 45 (87%) | 27 (60%) | 39 (87%) | |
| Neutral | 19 (14%) | 21 (15%) | 2 (5%) | 9 (21%) | 5 (10%) | 7 (14%) | 12 (27%) | 5 (11%) | |
| Unacceptable | 14 (10%) | 4 (3%) | 3 (7%) | 3 (7%) | 5 (10%) | 0 (0%) | 6 (13%) | 1 (2%) | |
| Patient friendliness | Total | 136 | 133 | 43 | 43 | 39 | 39 | 54 | 51 |
| Acceptable | 61 (45%) | 124 (93%) | 20 (47%) | 37 (86%) | 23 (59%) | 37 (95%) | 18 (33%) | 50 (98%) | |
| Neutral | 33 (24%) | 6 (5%) | 11 (26%) | 5 (12%) | 9 (23%) | 1 (3%) | 13 (24%) | 0 (0%) | |
| Unacceptable | 42 (31%) | 3 (2%) | 12 (28%) | 1 (2%) | 7 (18%) | 1 (3%) | 23 (43%) | 1 (2%) | |
| Programmatic aspects | Total | 141 | 132 | 44 | 42 | 41 | 41 | 56 | 53 |
| Acceptable | 85 (60%) | 110 (83%) | 30 (68%) | 29 (69%) | 28 (68%) | 33 (89%) | 27 (48%) | 48 (91%) | |
| Neutral | 32 (23%) | 19 (14%) | 8 (18%) | 11 (26%) | 10 (24%) | 3 (8%) | 14 (25%) | 5 (9%) | |
| Unacceptable | 24 (17%) | 3 (2%) | 6 (14%) | 2 (5%) | 3 (7%) | 1 (3%) | 15 (27%) | 0 (0%) | |
| Patient support | Total | 146 | 144 | 41 | 41 | 48 | 48 | 57 | 54 |
| Acceptable | 100 (69%) | 122 (85%) | 29 (71%) | 33 (81%) | 34 (71%) | 45 (92%) | 37 (65%) | 44 (82%) | |
| Neutral | 27 (19%) | 19 (13%) | 9 (22%) | 8 (20%) | 6 (13%) | 3 (6%) | 12 (21%) | 8 (15%) | |
| Unacceptable | 19 (13%) | 3 (2%) | 3 (7%) | 0 (0%) | 8 (17%) | 1 (2%) | 8 (14%) | 2 (4%) | |
| Human resources | Total | 153 | 153 | 42 | 42 | 49 | 51 | 62 | 60 |
| Acceptable | 90 (59%) | 121 (79%) | 29 (69%) | 27 (64%) | 29 (59%) | 46 (90%) | 32 (52%) | 48 (80%) | |
| Neutral | 43 (28%) | 26 (17%) | 9 (21%) | 13 (31%) | 14 (29%) | 4 (8%) | 20 (32%) | 9 (15%) | |
| Unacceptable | 20 (13%) | 6 (4%) | 4 (10%) | 2 (5%) | 6 (12%) | 1 (2%) | 10 (16%) | 3 (5%) | |
| PSCM | Total | 79 | 74 | 25 | 25 | 28 | 26 | 26 | 24 |
| Acceptable | 53 (67%) | 59 (80%) | 18 (72%) | 14 (56%) | 20 (71%) | 23 (92%) | 15 (58%) | 22 (92%) | |
| Neutral | 14 (18%) | 13 (18%) | 4 (16%) | 10 (40%) | 5 (18%) | 2 (8%) | 5 (19%) | 1 (4%) | |
| Unacceptable | 12 (15%) | 2 (3%) | 3 (12%) | 1 (4%) | 3 (11%) | 1 (0%) | 6 (23%) | 1 (4%) | |
a Since certain topics of the acceptability matrix were only collected for certain stakeholder groups and optional or not required for others (Table 1), only missing values for “mandatory” topics for the respective stakeholder were considered “true missing” values. Answers were excluded if the question was not a topic for the respective stakeholder
BPaL bedaquiline & pretomanid & linezolid, ITR Individualized Treatment Regimen, PSCM procurement and supply chain management